U.S. Markets close in 2 hrs 5 mins

Neuren Pharmaceuticals Limited (NEU.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.073+0.010 (+15.873%)
At close: 4:11PM AEST

Neuren Pharmaceuticals Limited

435 Williamstown Road
Unit 4
Port Melbourne, VIC 3207
61 3 9092 0480

Full Time Employees

Key Executives

Mr. Jonathan Charles Pilcher BSc (Hons), ACAChief Financial Officer and Company Sec.N/AN/AN/A
Dr. Nancy E. Jones Ph.D.VP of Clinical Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its lead product is Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion. The company is also developing NNZ-259 that is in preclinical development for the treatment of various neurological disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Port Melbourne, Australia.

Corporate Governance

Neuren Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.